Candel (CADL) Up as Pancreatic Cancer Drug Gets Orphan Drug Tag [Yahoo! Finance]
Candel Therapeutics, Inc. (CADL)
Company Research
Source: Yahoo! Finance
candidate, CAN-2409, for the treatment of pancreatic ductal adenocarcinoma (PDAC). Shares of the company rallied 42.8% on Apr 12, following the news. The FDA grants the orphan drug designation to support the development of medicines for rare disorders that affect fewer than 200,000 patients in the United States. The orphan drug designation will grant Candel market exclusivity for CAN-2409 in the treatment of PDAC for a predefined time period, along with the exemption of FDA application fees and tax credits for qualified clinical studies, all subject to approval. Per management, the orphan designation grant reaffirms the potential of Candel's CAN-2409 to treat rare and difficult-to-treat forms of cancer. Please note that last year, the FDA also granted the Fast Track designation to CAN-2409 for the same indication. The Fast Track designation facilitates rapid development and expedites the review of drug candidates that are being developed to treat serious conditions and for which
Show less
Read more
Impact Snapshot
Event Time:
CADL
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CADL alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CADL alerts
High impacting Candel Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
CADL
News
- Candel Therapeutics Announces Upcoming Presentations at the 2024 ASCO Annual Meeting [Yahoo! Finance]Yahoo! Finance
- Candel Therapeutics Announces Upcoming Presentations at the 2024 ASCO Annual MeetingGlobeNewswire
- GLYC, APLD and AUTL are among after hour movers [Seeking Alpha]Seeking Alpha
- NKTR, VERU and EGIO among mid-day movers [Seeking Alpha]Seeking Alpha
- Candel Therapeutics Receives FDA Orphan Drug Designation for CAN-2409 for the Treatment of Pancreatic Cancer [Yahoo! Finance]Yahoo! Finance
CADL
Earnings
- 11/9/23 - Miss
CADL
Sec Filings
- 4/25/24 - Form 8-K
- 4/25/24 - Form 10-K/A
- 4/11/24 - Form 8-K
- CADL's page on the SEC website